Intranasal Glutathione in Parkinson's Disease

Status Completed

Clinical Trial Summary

Excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of delivery for this popular CAM therapy in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)GSH in volunteers with PD in a Phase I single ascending dose escalation study.

Clinical Trial Description

Individuals will be randomized to one of three treatment (100 mg GSH/ ml, 200 mg GSH/ ml, or placebo) arms in a double-blind fashion. All study medication will be administered 1 ml three times daily for three months, with a one-month wash out. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01398748
Study type	Interventional
Source	Bastyr University
Contact
Status	Completed
Phase	Phase 1
Start date	July 2012
Completion date	January 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02170376` - The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics	Phase 1
Completed	`NCT02169479` - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa	Phase 1
Completed	`NCT02169895` - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide	Phase 1
Completed	`NCT02778594` - Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide	Phase 1
Completed	`NCT02274766` - Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia	Phase 3
Completed	`NCT02169453` - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa	Phase 1
Completed	`NCT04380142` - Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease	Phase 3
Withdrawn	`NCT06118294` - Efficacy of Probiotics for Parkinson Disease (PD)	N/A
Recruiting	`NCT05916157` - An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Completed	`NCT03033498` - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	Phase 1
Completed	`NCT02169427` - An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites	Phase 1
Completed	`NCT02834507` - Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients	Phase 2
Active, not recruiting	`NCT04379050` - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease	Phase 3
Completed	`NCT02169440` - Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin	Phase 1
Completed	`NCT02202551` - Open-Label Safety Study of ADS-5102 in PD Patients With LID	Phase 3
Recruiting	`NCT06107426` - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Completed	`NCT02169466` - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide	Phase 1
Recruiting	`NCT03732898` - Coordinated Reset Deep Brain Stimulation	N/A
Completed	`NCT02799381` - A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)	Phase 3
Terminated	`NCT03829657` - Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure	Phase 3